Lincoln Pharmaceuticals Ltd
Ticker: LINCOLN
Decent
48/100
☆ Add to Watchlist
Investing Reference
Price
527.35
Market Cap
1056.27
Debt/Equity
0.0000
ROE %
13.023
PB
1.5726
Promoter %
49.776
Pledge %
0.000
1Y Rev Growth %
4.999
5Y Rev Growth %
10.188
NP Margin %
12.752
NP Margin 5Y Avg %
14.095
Trading Reference
1M Return %
-6.079
6M Return %
-6.829
1Y Return %
-21.461
% Away 52W High
85.740
% Away 52W Low
5.681
Daily Volume
27611
Investment Verdict
Buy
Score 82/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 21/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Lincoln Pharmaceuticals Ltd is currently trading near its support level, with the 50-day EMA indicating a bullish trend. If the stock breaks through the resistance level, there is a strong potential for upside. However, if it fails to hold the support, downside risk remains significant.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
I
Innovana Thinklabs Ltd
The stock shows potential in a growing sector but faces significant risks and inconsistencies in financial performance.
View details
M
Matrimony.Com Ltd
Matrimony.Com Ltd shows potential in a growing sector, but faces significant challenges in growth consistency and valuation, making it a risky investment.
View details
M
Mamata Machinery Ltd
Mamata Machinery Ltd shows several weaknesses across key metrics, indicating a risky investment with limited growth prospects.
View details
C
Cool Caps Industries Ltd
Cool Caps Industries Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
E
Elin Electronics Ltd
Elin Electronics Ltd shows potential in a growing sector, but faces challenges in profitability and valuation. Caution is advised.
View details
I
Industrial and Prudential Investment Co Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
R
Regaal Resources Ltd
Regaal Resources Ltd presents several risks with inconsistent growth and profitability metrics, alongside high valuation concerns.
View details
K
KMC Speciality Hospitals (India) Ltd
KMC Speciality Hospitals shows potential in a growing sector, but faces challenges in execution and profitability consistency.
View details
A
Aym Syntex Ltd
Aym Syntex Ltd shows potential but faces several challenges that could impact future performance.
View details
A
Amal Ltd
Amal Ltd presents several risks with inconsistent growth and high valuation metrics, making it a risky investment at this time.
View details
V
V-Marc India Ltd
V-Marc India Ltd shows potential but faces challenges in growth consistency and profitability metrics.
View details
B
Bajaj Steel Industries Ltd
Bajaj Steel Industries Ltd shows potential for growth but faces challenges in profitability and execution risks. Investors should proceed with caution.
View details
R
Radhika Jeweltech Ltd
Radhika Jeweltech Ltd shows potential but faces significant challenges in growth consistency and market sentiment.
View details
A
Abans Financial Services Ltd
Abans Financial Services Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
E
Everest Industries Ltd
Everest Industries Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
S
Shree Pushkar Chemicals & Fertilisers Ltd
Shree Pushkar Chemicals & Fertilisers Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and execution risks.
View details
Business Overview
Lincoln Pharmaceuticals Ltd is a prominent player in the Indian pharmaceutical sector, dedicated to manufacturing high-quality generic medicines and healthcare products. Catering to both domestic and international markets, the company focuses on delivering affordable healthcare solutions. With a commitment to innovation and sustainability, Lincoln is well-positioned to meet the growing healthcare needs of the population.
- Established reputation in the pharmaceutical industry
- Wide range of generic medicines
- Strong focus on quality and compliance
- Expanding international presence
- Commitment to affordable healthcare solutions
Investment Thesis
Lincoln Pharmaceuticals Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company for sustained growth and profitability in the evolving pharmaceutical landscape.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services align with industry trends, offering substantial growth potential.
- Attractive valuation metrics compared to industry peers indicate a buying opportunity.
- Robust financial performance and consistent dividend payouts strengthen its investment case.
- Strategic focus on innovation and quality positions Lincoln for long-term success.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into international markets
- Strong product pipeline
- Strategic partnerships with distributors
- Increasing focus on R&D
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in the sector
- Fluctuating raw material prices
- Dependence on key customers
- Market volatility affecting stock price
Peer Perspective
Lincoln Pharmaceuticals Ltd trades at a discount to peers like Sun Pharmaceutical and Cipla, primarily due to lower growth rates. A re-rating could occur if the company achieves consistent margin stability and accelerates its revenue growth.
Future Outlook
Lincoln Pharmaceuticals Ltd is poised for growth, driven by expanding product lines and market reach. Successful execution and effective cost control will be crucial in realizing this potential.
AI FAQs for Retail Users
- Q: What does Lincoln Pharmaceuticals Ltd do?A: Lincoln Pharmaceuticals Ltd is involved in manufacturing and marketing pharmaceutical products, including formulations and active pharmaceutical ingredients.
- Q: Is Lincoln Pharmaceuticals Ltd a good investment?A: Investment suitability depends on individual financial goals and risk tolerance. Always conduct thorough research before investing.
- Q: What are the recent financial results of Lincoln Pharmaceuticals Ltd?A: For the latest financial results, please check their official website or recent financial news updates.
- Q: How can I buy shares of Lincoln Pharmaceuticals Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What are the risks associated with investing in Lincoln Pharmaceuticals Ltd?A: Risks include market volatility, regulatory changes, and company-specific factors. Assess these before investing.
📊 Stock Investment Checklist (100 Points)
Lincoln Pharmaceuticals Ltd • Updated: 2025-09-17 15:52:05
-
8BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighConsistent revenue growth, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
9ValuationHighValuation metrics are in line with peers, but not compelling.
-
7BalanceHighModerate debt levels, liquidity is adequate.
-
6GovernanceGoodPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are notable.
-
1TechnicalsLowWeak market sentiment and low liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
Lincoln Pharmaceuticals shows potential but faces challenges in profitability and market sentiment.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100